Top

Breast Cancer Research and Treatment

Published in:

01-01-2019 | Clinical trial

Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial

Authors: Jian-wei Li, Wen-jia Zuo, Diana Ivanova, Xiao-qing Jia, Li Lei, Guang-yu Liu

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Abstract

Purpose

This study was designed to determine the safety and clinical efficacy of metronomic chemotherapy combined with aromatase inhibitors (AIs) for hormone receptor (HR)-positive advanced breast cancer (ABC) patients who cannot tolerate conventional-dose chemotherapy.

Methods

Postmenopausal patients with HR-positive ABC, who exhibited disease progression after first-line AIs treatment and who could not tolerate or rejected conventional chemotherapy, were enrolled in this study. Patients received capecitabine 500 mg PO TID (could be reduced to 500 mg QD in case of adverse effects) and exemestane 25 mg QD (after PD with letrozole) or letrozole 2.5 mg QD (after PD with exemestane). The primary endpoints were safety and tolerance, the secondary endpoints were objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), and time to treatment failure (TTF).

Results

In our analysis of 44 patients, the median age was 64 years (range 38–90) and 68.2% patients had at least two recurrences or metastatic lesions. Grade 3 toxicities (hand–foot syndrome) were observed only in 4 of the patients. Most patients exhibited no or mild toxicities. After a median follow-up of 14.8 months, ORR was 70.5%, CBR—77.3%, PFS—16.2 months, and TTF—14.4 months.

Conclusions

Metronomic oral capecitabine combined with AIs showed good efficacy, minimal toxicities, and good tolerance in HR-positive patients with ABC. It is a potential treatment option especially for postmenopausal HR-positive ABC patients in poor general condition who cannot tolerate conventional chemotherapy. Trial registration: Clinicaltrials.gov NCT01924078.

Tang LC, Yin WJ, Di GH, Shen ZZ, Shao ZM (2010) Unfavourable clinicopathologic features and low response rate to systemic adjuvant therapy: results with regard to poor survival in young Chinese breast cancer patients. Breast Cancer Res Treat 122(1):95–104. https://doi.org/10.1007/s10549-009-0537-4 PubMedCrossRef

Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. https://doi.org/10.1056/NEJMoa1109653 PubMedCrossRef

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35. https://doi.org/10.1016/S1470-2045(14)71159-3 PubMedCrossRef

Wolf C, Blohmer JU, Ortmann O, Krainick U, Eiermann W (2006) Neoadjuvant exemestan alone or combined with metronomic chemotherapy (epirubicine; paclitaxel; docetaxel): efficacy plus tolerability. Final results of a multicenter phase I/II study (GENARI: German neoadjuvant aromasin initiative). Breast Cancer Res Treat 100(Suppl. 1):S151. https://doi.org/10.1007/s10549-006-5678-0; Special issue: 29th Annual San Antonio Breast Cancer Symposium, Texas, USACrossRef

Hyder SM, Stancel GM (2000) Regulation of VEGF in the reproductive tract by sex-steroid hormones. Histol Histopathol 15(1):325–334. https://doi.org/10.14670/HH-15.325 PubMedCrossRef

Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878–1886. http://cancerres.aacrjournals.org/content/60/7/1878.full-text.pdf

Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105(8):1045–1047. https://doi.org/10.1172/JCI9872 PubMedPubMedCentralCrossRef

Montagna E et al (2014) Metronomic therapy and breast cancer: a systematic review. Cancer Treat Rev 2014. 40(8):942–950. https://doi.org/10.1016/j.ctrv.2014.06.002 PubMedCrossRef

Banys-Paluchowski M, Schutz F, Ruckhaberle E, Krawczyk N, Fehm T (2016) Metronomic chemotherapy for metastatic breast cancer - a systematic review of the literature. Geburtshilfe Frauenheilkd 2016 76(5):525–534. https://doi.org/10.1055/s-0042-105871 PubMedPubMedCentralCrossRef

10.

Liu Y, Gu F, Liang J, Dai X, Wan C, Hong X, Zhang K, Liu L (2017) The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: a meta-analysis. PLoS ONE 12(3): article e0173693. https://doi.org/10.1371/journal.pone.0173693

11.

Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A, Man S, Kerbel RS (2006) Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 66(3):1664–1674PubMedCrossRef

12.

Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale, Goldhirsch G A (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13(1):73–80PubMedCrossRef

13.

Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F (1999) Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94(12):4143–4155. http://www.bloodjournal.org/content/bloodjournal/94/12/4143.full.pdf

14.

Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, Cortinovis D, Digiacomo N, Bidoli P (2017) Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study. Tumori 103(1):e4–e8. https://doi.org/10.5301/tj.5000543 PubMedCrossRef

15.

Salem DA, Gado NM, Abdelaziz NN, Essa AE, Abdelhafeez ZM, Kamel TH (2008) Phase II trial of metronomic chemotherapy as salvage therapy for patients with metastatic breast cancer. J Egypt Natl Canc Inst 20(2):134–140. http://www.nci.cu.edu.eg/Journal/June2008/can_5.pdf

16.

Young SD, Lafrenie RM, Clemons MJ (2012) Phase II trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer. Curr Oncol 19(2):e75–e83. https://doi.org/10.3747/co.19.879 PubMedPubMedCentralCrossRef

17.

Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24(22):3623–3628. https://doi.org/10.1200/JCO.2005.04.5773 PubMedCrossRef

18.

Pritchard KI (2007) Combining endocrine agents with chemotherapy: which patients and what sequence? Cancer 112(Suppl. 3):718–722. https://doi.org/10.1002/cncr.23189 CrossRef

19.

Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A et al (2012) The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 23(6):1378–1386. https://doi.org/10.1093/annonc/mdr593 PubMedPubMedCentralCrossRef

20.

Kumar KS, Vogel CL, Moore MR, Bartolucci AA (1982) Sequential versus concomitant chemo-hormonal therapy in breast cancer. Breast Diseases of the Breast 8(2):2–7

21.

Bedognetti D, Sertoli MR, Pronzato P, Del Mastro L, Venturini M, Taveggia P et al (2011) Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. J Natl Cancer Inst 103(20):1529–1539. https://doi.org/10.1093/jnci/djr351 PubMedPubMedCentralCrossRef

22.

Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ et al (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9707):2055–2063. https://doi.org/10.1016/S0140-6736(09)61523-3 PubMedPubMedCentralCrossRef

23.

Kiang DT, Gay J, Goldman A, Kennedy BJ (1985) A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 313(20):1241–1246. https://doi.org/10.1056/NEJM198511143132001 PubMedCrossRef

24.

Nabholz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22):3758–3767. https://doi.org/10.1200/JCO.2000.18.22.3758 CrossRef

25.

Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J et al (2001) Preoperative treatment of post menopausal breast cancer patients with letrozole: a randomized double blind multicenter study. Ann Oncol 12(11):1527–1532PubMedCrossRef

26.

Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F et al (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003 63(19):6523–6531PubMed

27.

Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS et al (2016) Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomized, double-blind, phase 3 clinical trial. Lancet 387(10021):849–856. https://doi.org/10.1016/S0140-6736(15)01168-X PubMedCrossRef

28.

Poggio F, Ceppi M, Lambertini M, Bruzzi P, Ugolini D, Bighin C et al (2017) Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early breast cancer patients: a systematic review and meta-analysis. Breast 33:104–108. https://doi.org/10.1016/j.breast.2017.03.011 PubMedCrossRef

29.

Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V (2005) Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 16(8):1289–1296. https://doi.org/10.1093/annonc/mdi253 PubMedCrossRef

30.

Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R et al (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26(30):4899–4905. https://doi.org/10.1200/JCO.2008.17.4789 PubMedCrossRef

31.

Cazzaniga ME, Cortesi L, Ferzi A, Scaltriti L, Cicchiello F, Ciccarese M et al (2016) Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat 160(3):501–509. https://doi.org/10.1007/s10549-016-4009-3 PubMedPubMedCentralCrossRef

32.

Kataoka M, Yamaguchi Y, Moriya Y, Sawada N, Yasuno H, Kondoh K, Evans DB, Mori K, Hayashi S (2012) Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts. Oncol Rep 27(2):303–310. https://doi.org/10.3892/or.2011.1541 PubMedCrossRef

33.

Di Desidero T, Kerbel RS, Bocci G (2016) Metronomic chemotherapy for triple negative breast cancer? AGING 8(4):573–574. https://doi.org/10.18632/aging.100947 PubMedPubMedCentralCrossRef

34.

Munzone E, Bertolini F, Colleoni M (2014) Metronomic chemotherapy in breast cancer. In: Bocci G, Francia G (eds) Metronomic chemotherapy: pharmacology and clinical applications. Springer, Berlin, Heidelberg, pp 93–100. https://doi.org/10.1007/978-3-662-43604-2 CrossRef

35.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern-Cooperative-Oncology-Group. Am J Clin Oncol 5(6):649–655PubMedCrossRef

36.

Masuda N, Higaki K, Takano T et al (2014) A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. Cancer Chemother Pharmacol 74(2):229–238. https://doi.org/10.1007/s00280-014-2492-y PubMedCrossRef

37.

Yoshimoto M, Takao S, Hirata M et al (2012) Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol 70(2):331–338. https://doi.org/10.1007/s00280-012-1826-x PubMedCrossRef

38.

El-Arab LR, Swellam M, El Mahdy MM (2012) Metronomic chemotherapy in metastatic breast cancer: impact on VEGF. J Egypt Natl Canc Inst 24(1):15–22. https://doi.org/10.1016/j.jnci.2011.12.002 PubMedCrossRef

39.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRef

40.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62. https://doi.org/10.1016/S0140-6736(04)17666-6 PubMedCrossRef

41.

Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110(2):244–254. https://doi.org/10.1002/cncr.22789 PubMedCrossRef

42.

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425–439. https://doi.org/10.1016/S1470-2045(15)00613-0 PubMedCrossRef

43.

Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A et al (2004) Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol 15(1):79–87PubMedCrossRef

44.

Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, Pisconti S, Petrelli F, Vacca A, Lorusso V (2015) Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol 95(1):46–61. https://doi.org/10.1016/j.critrevonc.2015.01.008 PubMedCrossRef

45.

Montagna E, Palazzo A, Maisonneuve P, Cancello G, Iorfida M, Sciandivasci A et al (2017) Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: a phase II trial. Cancer Lett 400:276–281. https://doi.org/10.1016/j.canlet.2017.01.027 PubMedCrossRef

46.

Berruti A, Fazio N, Ferrero A, Pia Brizzi M, Volante M, Nobili E et al (2014) Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer 14:184. https://doi.org/10.1186/1471-2407-14-184 PubMedPubMedCentralCrossRef

47.

Schwartzberg LS, Wang G, Somer BG, Blakely LJ, Wheeler BM, Walker MS, Stepanski EJ, Houts AC (2014) Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Breast Cancer 14(1):13–19. https://doi.org/10.1016/j.clbc.2013.09.003 PubMedCrossRef

48.

Li J, Jia X, Ivanova D (2018) Chemoendocrine metronomic therapy of estrogen receptor-positive breast cancer by taxanes or capecitabine in combination with aromatase inhibitors. J Pharm Res 17(2): 78–82. https://doi.org/10.18579/jpcrkc/2018/17/2/127179; The 4th Mediterranean Symposium on Medicinal and Aromatic Plants (MESMAP-4), April 18–22, 2018, Antalya, Turkey, ISBN 978-605-61261-5-4, p. 125CrossRef

Title: Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial
Authors: Jian-wei Li
Wen-jia Zuo
Diana Ivanova
Xiao-qing Jia
Li Lei
Guang-yu Liu
Publication date: 01-01-2019
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-5024-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Extranodular extension in sentinel lymph node-positive breast cancer might predict further initiation of completion axillary lymph node dissection

Predictors of time to death after distant recurrence in breast cancer patients

Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis

A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients

Mucin 2 (MUC2) modulates the aggressiveness of breast cancer

A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer